Asia, Neglected Diseases Score Big In Nobel Prize Win
This article was originally published in PharmAsia News
Health campaigners and organizations working in the area of drugs for neglected diseases have hailed the Nobel Prize awarded to three researchers in the field, but the move also highlights shortcomings and research gaps.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.